Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.18 USD | +1.63% | -12.80% | -40.92% |
Business Summary
Number of employees: 130
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Immunotherapies and Vaccines
100.0
%
| 45 | 100.0 % | 1 | 100.0 % | -98.21% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom and United States
100.0
%
| 45 | 100.0 % | 1 | 100.0 % | -98.21% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
William Enright
CEO | Chief Executive Officer | 61 | 01/19/01 |
Gemma Brown
DFI | Director of Finance/CFO | 34 | 01/21/01 |
Nadège Pelletier
CTO | Chief Tech/Sci/R&D Officer | 46 | 01/23/01 |
Investor Relations Contact | - | 01/22/01 | |
Graham Griffiths
PRN | Corporate Officer/Principal | 45 | 01/17/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Karen Dawes
BRD | Director/Board Member | 72 | 01/21/01 |
William Enright
CEO | Chief Executive Officer | 61 | 01/19/01 |
Anne Phillips
BRD | Director/Board Member | 70 | 21/21/21 |
Robin Wright
CHM | Chairman | 59 | 01/18/01 |
Director/Board Member | 61 | 01/18/01 | |
Alex Hammacher
BRD | Director/Board Member | 43 | 01/20/01 |
Joseph Scheeren
BRD | Director/Board Member | 68 | 31/21/31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,643,540 | 37,217,593 ( 96.31 %) | 0 | 47.98 % |
Stock B | 1 | 38,921,212 | 0 | 0 |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.92% | 84.85M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- BRNS Stock
- Company Barinthus Biotherapeutics plc